ArticlePloS one2025
Age-specific benefits of Vitamin D and its association with mortality.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin D is a fat-soluble secosteroid that plays essential roles in calcium homeostasis, bone metabolism, and numerous other physiological processes. Vitamin D deficiency has been associated with increased risk of various diseases and mortality. However, population-based studies examining the relationship between vitamin D and mortality across different age groups remain limited.
methodsTo investigate the correlation between 25-hydroxyvitamin D [25(OH)D] levels, vitamin D status, and mortality in a cohort of 47,478 individuals aged 18-85 years.
resultsHigher 25(OH)D levels were associated with lower mortality risk. Compared to the vitamin D deficiency group, the Hazard ratios (HR) for all-cause mortality were 0.71 (95%CI: 0.66-0.76) in the insufficiency group and 0.64 (95%CI: 0.58-0.70) in the sufficiency group. The association varied by age: strongest in adults aged 40-59 years (HR: 0.74, 95% CI: 0.65-0.85), significant in those ≥60 years (HR: 0.86, 95% CI: 0.82-0.90), but non-significant in those aged 18-39 years. The RCS analysis revealed a non-linear relationship between 25(OH)D and mortality, with significant risk reduction observed between 59.25-261.45 nmol/L for the overall population. The optimal 25(OH)D levels (lowest HR) varied by subgroups: 96.81 nmol/L for the overall population, 102.9 nmol/L for females, 67 nmol/L for ages 40-59, and 104.23 nmol/L for ages ≥60 years, while no significant association was found in ages 18-39 years.
conclusionOur findings suggest that Vitamin D are associated with mortality among the whole population. Individuals aged 40-59 may derive potential benefits from vitamin D supplementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.